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Safety of Accelerated Schedules of Subcutaneous Allergen 
Immunotherapy with House Dust Mite Extract in Patients with 
Atopic Dermatitis
The safety of accelerated schedules of allergen immunotherapy (ASAI) in patients with 
bronchial asthma (BA) has been reported but there are little data on the safety of ASAI for 
patients with atopic dermatitis (AD). In this study, we investigated the safety of ASAI in 
patients with AD. Sixty patients with AD and 18 patients with BA sensitized to house dust 
mites (HDM) were studied. A maximum maintenance dose of HDM extract, adsorbed to 
aluminum hydroxide, was administered to patients by subcutaneous injection with either  
a 3-day protocol (rush immunotherapy) or 1-day protocol (ultra-rush immunotherapy). 
Systemic reactions were observed 4 of 15 patients (26.7%) with AD during rush 
immunotherapy, 13 of 45 patients (28.9%) with AD during ultra-rush immunotherapy, 
and 4 of 18 patients (22.2%) with BA during rush immunotherapy (P > 0.05). No severe or 
near fatal systemic reactions occurred in 78 subjects of this study. Systemic reactions 
developed within 4 hr after administration of the maximum allergen dose in 20 of 21 
patients (95.2%) with AD and BA who showed systemic reactions during rush or ultra-rush 
immunotherapy. In conclusion, ASAI was safe and well tolerated in patients with AD. ASAI 
can be a useful therapeutic option for AD.
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INTRODUCTION
Allergen immunotherapy is a treatment of administering grad-
ually increasing doses of allergen in order to decrease a hyper-
sensitivity to the allergen and thereby reduce clinical symptoms 
from exposure to the allergen (1). The clinical efficacy of aller-
gen immunotherapy has been proven for the treatment of aller-
gic rhinitis (AR), bronchial asthma (BA), and Hymenoptera hy-
persensitivity (1, 2). It can alter the natural history of respiratory 
allergic diseases, prevent the development of new allergen sen-
sitizations, and produce a sustained clinical improvement after 
discontinuation of treatment (2).
  Despite various benefits of allergen immunotherapy, clinical 
application has been limited by the risk of severe allergic reac-
tions and inconvenience of frequent hospital visits during the 
initial build-up phase of treatment (3). In a traditional schedule 
of allergen immunotherapy, weekly injections of increasing dos-
es of allergen extract are required for about 12-16 weeks (initial 
build-up phase) to reach a maximum maintenance dose of al-
lergen. The schedule is then changed to monthly injections of 
maintenance dose for 3-5 yr (3). The inconvenience of requir-
ing frequent hospital visits during the initial build-up phase is 
one of the main reasons limiting a wider application of allergen 
immunotherapy in clinical practice. To overcome this inconve-
nience, accelerated schedules of allergen immunotherapy (ASAI) 
have been developed whereby the initial build-up phase is com-
pleted within 1-3 days (rush immunotherapy) (3). The use of 
rush immunotherapy has been suggested to provide a better 
compliance and a faster onset of clinical benefits during aller-
gen immunotherapy (3). However, the rush immunotherapy 
could be associated with an increased incidence of systemic re-
actions (27%-100%) compared to the traditional schedule of al-
lergen immunotherapy (0.84%-46.7%) and requires a use of hos-
pital facilities to closely monitor patients for systemic reactions 
(3). The incidence of systemic reactions from rush immunother-
apy can be reduced by the use of premedications including an-
tihistamines and corticosteroids (4). 
  Atopic dermatitis (AD) is a common, chronic relapsing inflam-
matory skin disease characterized by intense itching, dry skin, 
inflammation, and exudation (5). Inhalation or direct skin con-
tact of house dust mite (HDM) allergens can exacerbate AD in 
patients with hypersensitivity to HDM (6, 7). Significant clinical 
improvement has been observed in patients with AD and hyper-
sensitivity to HDM by reducing exposure to HDM allergens (8). Kim M-E, et al.  •  Safety of Rush Immunotherapy for Atopic Dermatitis 
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These evidences strongly suggest an important pathogenic role 
of allergic responses to HDM in patients with AD and hypersen-
sitivity to HDM.
  An increasing amount of evidence has been reported on the 
clinical efficacy of allergen immunotherapy for the treatment of 
AD (9). Allergen immunotherapy with HDM extract has been 
proven to be clinically beneficial in patients with severe AD in a 
randomized controlled study (10). Although there are controver-
sial issues on the clinical usefulness of allergen immunotherapy 
in the management of AD, AD sensitized to aeroallergen has been 
suggested as a potential indication for allergen immunotherapy 
in the recently published clinical practice parameter (11).
  There have been numerous data on the safety of ASAI in pa-
tients with BA or AR (3). However, there have been little pub-
lished data on the application of ASAI for patients with AD. We 
hypothesized that ASAI could be a safe therapeutic option in 
patients with AD as well as in patients with BA. In this study, we 
evaluated the safety of ASAI in patients with AD and hypersen-
sitivity to HDM.
MATERIALS AND METHODS
Patients
Sixty patients with AD and 18 patients with BA were studied 
(Table 1). All patients were over 12 yr of age. Patients with AD 
showed typical clinical features compatible with the diagnostic 
criteria of Hanifin and Rajka (12). All subjects with BA had a typ-
ical clinical history and either a 20% decrease in forced expira-
tory volume in one second (FEV1) following the inhalation of 
less than 8 mg methacholine/mL, or a documented reversibili-
ty of FEV1 greater than 15% after inhalation of a bronchodilator. 
Patients showed positive skin reactions (mean wheal diameter 
≥ 3 mm over the saline control) to two kinds of HDM extract (Der-
matophagoides farinae and Dermatophagoides pteronyssinus; 
Allergopharma Joachim Ganzer KG, Reinbeck, Germany) on 
the skin prick test and positive results on serum-specific IgE an-
tibody tests to HDM (≥ 0.7 kU/L) by CAP-FEIA (Phadia, Uppsa-
la, Sweden). Inclusion and exclusion criteria of patients for al-
lergen immunotherapy in this study were consistent with the 
WHO and EAACI position papers for allergen immunotherapy 
(1, 13). Patients with AD were on standard therapeutic regimens 
including topical moisturizers, topical corticosteroids, and/or 
topical calcineurin inhibitors for more than 3 months, and their 
clinical symptoms were not effectively controlled. Patients with 
BA received appropriate medications including inhaled corti-
costeroids, bronchodilators, and leukotriene antagonists accord-
ing to an international guideline for the management of BA (14). 
Study design
The study was designed as an open-label non-randomized ob-
servational study to assess the safety of ASAI with HDM extract 
in patients with AD and BA. 
Preparation of allergen extract for immunotherapy
HDM allergen extract containing a mixture of D. farinae and D. 
pteronyssinus extracts (50%:50%) adsorbed to aluminum hy-
droxide (Novo-Helisen Depot
®; Allergopharma Joachim Gan-
zer KG, Reinbeck, Germany) was used for allergen immunother-
apy. Biological potency of the HDM extract for maintenance im-
munotherapy was 5000 therapeutic units/mL according to the 
manufacturer. The HDM allergen extract was composed of three 
vials (labeled as No. 1, 2, and 3) containing three different con-
centrations of allergen with tenfold increases in concentration 
between each vial. The manufacturer recommends subcutane-
ous administration of increasing doses (0.1, 0.2, 0.4, and 0.8 mL 
of each vial) of HDM allergen extract each week for 12 weeks, 
and then 0.8 mL of the highest allergen concentration (vial No. 
3) once a month as maintenance therapy.
Procedure for accelerated schedules of allergen 
immunotherapy
All patients received premedications consisting of fexofenadine 
120 mg/day and ebastine 10 mg/day for at least 7 days prior to 
and during the immunotherapy. For accelerated schedules of 
allergen immunotherapy, patients were admitted to the hospi-
tal and received intravenous administration of normal saline to 
achieve vascular access during treatment. The schedules for sub-
cutaneous injections of HDM extract during rush immunother-
apy (3-day protocol) and ultra-rush immunotherapy (1-day pro-
tocol) are shown in Table 2. The ultra-rush immunotherapy was 
Table 1. Characteristics of patients with atopic dermatitis (AD) or bronchial asthma (BA) who received rush or ultra-rush immunotherapy (ITx)
Parameters
Patients with AD  
who received rush ITx
Patients with AD  
who received ultra-rush ITx
Patients with BA  
who received rush ITx
P value
Number of patients  15 45 18
Age (yr) 21.0 ± 5.8 24.2 ± 7.9 25.5 ± 10.3 > 0.05
Male (number, %) 10 (66.7) 23 (51.1) 5 (27.8) > 0.05
Total IgE (kU/L)    1883.3 ± 1937.7*    2829.5 ± 1893.2* 409.9 ± 353.9 < 0.05
Specific IgE (kU/L)
   D. pteronyssinus
   D. farinae
 
 57.0 ± 35.7
 71.3 ± 33.4
 
  61.3 ± 36.3
  71.2 ± 35.2
 
48.1 ± 42.0
47.4 ± 37.9
 
> 0.05
> 0.05
Peripheral blood eosinophil counts (/µL)   496.4 ± 518.8   674.1 ± 844.9 357.2 ± 249.3 > 0.05
Data are expressed as mean ± SD. *P < 0.05 compared to patients with BA who received rush immunotherapy.Kim M-E, et al.  •  Safety of Rush Immunotherapy for Atopic Dermatitis 
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performed using three different protocols according to the in-
jection intervals and the maximum allergen doses of HDM ex-
tract (Table 2). All patients were observed for over 16 hr (over-
night) after administration of the maximum allergen dose prior 
to discharge from the hospital.
Assessment of systemic reactions
To assess safety, details of systemic reactions, doses of adminis-
tered allergen, and onset time of systemic reactions were record-
ed. Severity of systemic reaction was graded according to the 
EAACI criteria for the classification of systemic reactions asso-
ciated with allergen immunotherapy as previously reported (15, 
16).
Statistical analysis
Incidence of systemic reaction was presented in absolute num-
bers and percentages. Kruskal-Wallis test or Mann-Whitney U 
test was used for comparisons of baseline characteristics of pa-
tients (age, total IgE, and specific IgE) between the groups. The 
chi-square test was used to compare incidences of systemic re-
actions between study groups, and a P value of less than 0.05 
was considered statistically significant.
Ethics statement
This study was approved by the institutional review board (IRB 
number: AJIRB-CRO-07-072 and AJIRB-MED-OBS-09-248). All 
subjects provided written informed consent to participate in this 
study. 
RESULTS
Incidence of systemic reactions
Systemic reactions were observed 4 of 15 patients (26.7%) with 
AD during rush immunotherapy, 13 of 45 patients (28.9%) with 
AD during ultra-rush immunotherapy, and 4 of 18 patients (22.2 
%) with BA during rush immunotherapy (Table 3). No signifi-
cant difference was observed in the incidence of systemic reac-
tions among the three groups (P > 0.05) (Table 3). During ultra-
rush immunotherapy in patients with AD, systemic reactions 
were observed in 6 of 16 patients (37.5%) with AD receiving 12 
injections at 0.5-hr intervals, 2 of 9 patients (22.2%) with AD re-
ceiving 4 injections at 2-hr intervals, and 5 of 20 patients (25.0%) 
with AD receiving three injections at 1-hr intervals with a 50% 
reduced maximal allergen dose (Table 3). No significant differ-
ence was observed in the incidence of systemic reactions among 
the three groups (P > 0.05).
Types of systemic reactions
Seventeen of the 60 patients with AD (28.3%) showed systemic 
reactions during rush or ultra-rush immunotherapy. Localized 
or generalized urticaria was observed in 16 patients (26.7%) and 
mild bronchospasm (mild dyspnea without wheezing) was seen 
in 3 patients (5.0%) among 60 patients with AD during rush or 
ultra-rush immunotherapy (Table 4).
  Four of the 18 patients with BA (22.2%) showed systemic re-
actions during rush immunotherapy. Localized or generalized 
urticaria was observed in 3 patients (16.7%) and moderate bron-
chospasm (moderate dyspnea with mild wheezing) in one pa-
tient (5.6%) during rush immunotherapy (Table 5).
  Severity grades of systemic reactions associated with rush or 
ultra-rush immunotherapy were compatible with grade 1 or 
grade 2 according to the EAACI criteria for the classification of 
systemic reactions associated with allergen immunotherapy 
(Tables 4, 5). No severe or near fatal systemic reactions (grade 3 
or grade 4 of EAACI criteria) occurred in 78 subjects of this study. 
All systemic reactions resolved rapidly following intravenous 
administration of 4 mg of chloropeniramine and 5 mg of dexa-
methasone for urticaria or inhalation of 200 µg of salbutamol 
Table 2. Schedules for rush or ultra-rush immunotherapy
Protocol
Allergen  
concentration 
(therapeutic  
units/mL)
Volume of  
injection  
(mL)
Interval of 
injection 
 (hr)
Protocol of rush immunotherapy (3 days) 
   Day 1
   Day 2
   Day 3
     50
   500
5,000
0.1, 0.2, 0.4, 0.8 
0.1, 0.2, 0.4, 0.8 
0.1, 0.2, 0.4, 0.8 
2 
2 
2 
Protocol of ultra-rush immunotherapy (1 day)
   Protocol 1
 
 
   Protocol 2
   Protocol 3
      50
   500
5,000
5,000
5,000
0.1, 0.2, 0.4, 0.8 
0.1, 0.2, 0.4, 0.8 
0.1, 0.2, 0.4, 0.8 
0.1, 0.2, 0.4, 0.8
0.1, 0.2, 0.4
   0.5
   0.5
   0.5
2
1
Protocol 1, 12 injections at 0.5-hr intervals for 6 hr; Protocol 2, 4 injections at 2-hr 
intervals for 8 hr; Protocol 3, 3 injections at 1-hr intervals for 3 hr with 50% reduced 
maximal allergen dose.
Table 3. Incidences of systemic reactions in patients with atopic dermatitis (AD) or bronchial asthma (BA) during rush or ultra-rush immunotherapy (ITx)
Patients with various ITx No. of patients  Systemic reactions* (number, %)
Patients with BA who received rush ITx 18   4 (22.2)
Patients with AD who received rush ITx 15   4 (26.7)
Patients with AD who received ultra-rush ITx
   Protocol 1 (12 injection at 0.5-hr intervals for 6 hr)
   Protocol 2 (4 injections at 2-hr intervals for 8 hr)
   Protocol 3 (3 injections at 1-hr intervals for 3 hr)
45
16
  9
20
13 (28.9)
  6 (37.5)
  2 (22.2)
  5 (25.0)
*No statistically significant difference was observed in the incidence of systemic reactions among the groups (P > 0.05).Kim M-E, et al.  •  Safety of Rush Immunotherapy for Atopic Dermatitis 
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for bronchospasm.
Maximal administered dose of allergen
Fifty-eight patients with AD received the planned maximal dose 
of allergen according to the schedules for rush or ultra-rush im-
munotherapy. However, 50% of the maximal planned dose was 
administered in two patients with AD due to the development 
of systemic reactions (Table 4). All 18 patients with BA received 
the planned maximal dose of allergen (Table 5). 
Onset of systemic reaction
Systemic reactions developed within 4 hr after administration of 
the maximal allergen dose in 20 of 21 patients (95.2%) with AD 
and BA who showed systemic reactions during rush or ultra-
rush immunotherapy (Tables 4, 5). Generalized urticaria was 
observed at 9 hr after administration of the planned maximal 
dose of allergen in one patient with AD during rush immuno-
therapy (Table 4).
DISCUSSION 
In this study, ASAI using HDM extract were safe and tolerable 
in patients with AD. Incidence of systemic reactions during rush 
or ultra-rush immunotherapy using HDM extract was not signif-
icantly different in patients with AD (28.3%) compared to those 
with BA (22.2%). These results seem to be similar or a little bit 
lower than the incidences of systemic reactions (27%-100%) of 
previous studies in patients with BA and/or AR during rush im-
munotherapy using inhalant allergen extracts (3). This suggests 
that ASAI could be a safe therapeutic option for patients with AD.
  We used an aluminum hydroxide adsorbed HDM extract for 
rush or ultra-rush immunotherapy in this study. A previous study 
reported that an overall cumulative incidence of systemic reac-
tions during conventional schedule of allergen immunotherapy 
for 5 yr using unmodified soluble HDM extract was 43.75% in 
the patients with both AR and AD, and was significantly higher 
Table 4. Type and severity grade of systemic reactions (SR) in patients with atopic dermatitis (AD) during rush or ultra-rush immunotherapy. 
Patient No. Sex Age (yr) Type of SR
Grade  
of SR  
(EAACI criteria)
Planed maximum 
allergen dose  
(therapeutic units)
Allergen dose  
that induced SR  
(therapeutic units)
Onset time  
of SR (min)
Treatment  
for SR
Rush immunotherapy (3 days, n = 15) 
   21
   23
   24
   26
M
M
F
F
15
17
27
33
Generalized urticaria 
Mild bronchospasm
Generalized urticaria
Generalized urticaria
2
1
2
2
4000
4000
4000
4000
4000
4000
2000
4000
  60
120
  60
540
C, D
S
C, D 
C, D
Ultra-rush immunotherapy (1 day, n = 45 )
   Protocol 1 (12 injection at 0.5-hr intervals for 6 hr, n = 16)
      29
 
      36
 
      37
      43
      45
      48
F
 
F
 
M
M
M
F
25
 
22
 
28
25
26
19
Localized urticaria,  
mild bronchospasm
Localized urticaria, 
mild bronchospasm
Localized urticaria
Localized urticaria
Generalized urticaria
Generalized urticaria
1
1
1
1
2
2
4000
4000
4000
4000
4000
4000
4000
4000
4000
4000
4000
4000
  30
110
  90
  30
  60
  90
C, D, S
C, D, S
C, D
C, D
C, D
C, D
   Protocol 2 (4 injections at 2-hr intervals for 8 hr, n = 9) 
      58
      59
F
M
27
31
Localized urticaria
Generalized urticaria
1
2
4000
4000
4000
2000
  30
120
C, D
C, D
   Protocol 3 (3 injections at 1-hr intervals for 3 hr, n = 20)
      60
      65
      70
      74
      75
M
F
M
F
F
26
27
16
29
24
Generalized urticaria
Localized urticaria
Localized urticaria
Localized urticaria
Generalized urticaria
2
1
1
1
2
2000
2000
2000
2000
2000
2000
2000
2000
2000
2000
  90
180
  30
240
  90
C, D
C, D
C, D
C, D
C, D
C, Intravenous administration of 4 mg of chloropeniramine; D, Intravenous administration of 5 mg of dexamethasone; S, Inhalation of 200 µg of salbutamol.
Table 5. Type and severity grade of systemic reactions (SR) in patients with bronchial asthma (BA) during rush immunotherapy
Patient No. Sex Age (yr) Type of SR
Grade of SR  
(EAACI criteria)
Planed maximum  
allergen dose  
(therapeutic units)
Allergen dose  
that induced SR 
(therapeutic units)
Onset time  
of SR (min)
Treatment  
for SR
  2 F 15 Localized urticaria 1 4000 4000   30 C, D
  9 M 16 Moderate bronchospasm 2 4000 4000 160 S 
11 F 25 Generalized urticaria 2 4000 4000 240 C, D
13 F 15 Generalized urticaria 2 4000 4000 120 C, D
C, Intravenous administration of 4 mg of chloropeniramine; D, Intravenous administration of 5 mg of dexamethasone; S, Inhalation of 200 µg of salbutamol.Kim M-E, et al.  •  Safety of Rush Immunotherapy for Atopic Dermatitis 
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than 2.82% in patients with AR without AD (17). Systemic reac-
tions occurred significantly more frequently in patients who re-
ceived allergen immunotherapy with aqueous extract than those 
with aluminum hydroxide adsorbed extract of honeybee ven-
om (18). We speculate that the use of aluminum hydroxide ad-
sorbed HDM extracts reduced the incidence of systemic reac-
tions in patients with AD during ASAI in this study.
  Traditionally, aqueous allergen extract was preferentially used 
for rush immunotherapy instead of aluminum hydroxide ad-
sorbed allergen extract (19). Aluminum hydroxide adsorbed al-
lergen extract has an advantage of slower systemic release of al-
lergen from the injection site compared to aqueous allergen ex-
tract (19). However, this characteristic of aluminum hydroxide 
adsorbed allergen extract could be associated with delayed on-
set of systemic reactions compared to aqueous allergen extract 
(19). In a previous report on the timing of onset of systemic re-
actions in 1,038 patients during allergen immunotherapy using 
aluminum hydroxide adsorbed allergens (mites, pollens, cat, 
and wasp and bee venoms) for 3 yr showed that 341 patients 
(33%) experienced systemic reactions and 94% of the systemic 
reactions were developed within 12 hr after injection of allergen 
extract (20). In our study, the systemic reaction was developed 
within 4 hr after administration of the maximum allergen dose 
in 95% of patients with AD and patients with BA during rush or 
ultra-rush immunotherapy. This suggests that ASAI with alumi-
num hydroxide adsorbed unmodified HDM allergen can be per-
formed in patients with AD in an outpatient clinic setting with 
appropriate observation time after administration of the maxi-
mum allergen dose.
  In this study, we tried three different protocols of ultra-rush 
immunotherapy in patients with AD and systemic reactions were 
observed in 37.5% of patients receiving 12 injections at 0.5-hr 
intervals, 22.2% of patients receiving four injections at 2-hr in-
tervals, and 25.0% of patients receiving three injections at 1-hr 
intervals with a 50% reduced maximum allergen dose. Although 
no statistically significant difference in incidence of systemic 
reactions was observed among the three groups, incidence of 
systemic reactions seemed to be increased in patients with AD 
who received a maximum allergen dose with shorter intervals in 
this study. When we extrapolate retrospectively from the results 
of this study, a protocol administrating HDM extract by three 
subcutaneous injections at 2-hr intervals with a 50% reduced 
maximum allergen dose may be a safer protocol for ultra-rush 
immunotherapy in patients with AD and patients with BA.
  Several trials have been conducted to reduce systemic reac-
tions during ASAI (3). Premedication with antihistamines and 
systemic corticosteroids decreased the incidence of systemic 
reactions during rush immunotherapy in patients with AR and 
BA by approximately 50% (4). Pretreatment with anti-IgE mono-
clonal antibody (omalizumab) resulted in a fivefold decrease in 
the risk of anaphylaxis during rush immunotherapy with aque-
ous ragweed extracts in patients with seasonal AR (21). Recently, 
a study on ultra-rush immunotherapy using aluminum hydrox-
ide adsorbed modified allergen (depigmented and polymerized) 
reaching the maintenance allergen dose on the first day with two 
injections at 0.5-hr intervals showed very low incidence of sys-
temic reaction (0.75% of 1,068 patients) in patients with respira-
tory allergic diseases without the need of hospitalization or pre-
medication (22). The use of various combinations of these ap-
proaches might further decrease the incidences of systemic re-
actions during ASAI in patients with AD.
  The management of severe AD is a challenging issue for cli-
nicians (23). Although oral corticosteroids, cyclosporin A, and 
mycophenolate mofetil are effective for the treatment of severe 
AD, the possibility of systemic toxicity from long-term treatment 
with these drugs limits their widespread use (23). A recent ran-
domized controlled study on the clinical efficacy of allergen im-
munotherapy suggests that it can be a useful therapeutic option 
for patients with severe AD sensitized to HDM (10). However, a 
compliance rate of the study was approximately 50% at the end 
of the 1-yr treatment period. This relatively low compliance rate 
seems to be related to the weekly injection interval for 1 yr in the 
study (10). This is also seen for traditional schedules of allergen 
immunotherapy in patients with respiratory allergic disease 
whereby compliance at 1 yr was reported to be 46%-59% (24). 
Application of ASAI in the treatment of patients with respiratory 
allergic diseases has been suggested to increase compliance by 
reducing time and cost for hospital visits and providing a rapid 
onset of clinical efficacy (3). Interestingly, rush immunotherapy 
has been successfully tried in dogs and cats with AD without 
severe systemic reactions (25, 26). Further studies on the long-
term safety and clinical efficacy are needed to evaluate a clini-
cal usefulness of ASAI in patients with AD.
  In conclusion, rush or ultra-rush immunotherapy was safe 
and well tolerated in patients with AD. ASAI can be a useful ther-
apeutic option for AD. 
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The safety of accelerated schedules of allergen immunotherapy (ASAI) in patients with bronchial asthma has been reported but 
there are little data on their safety for patients with atopic dermatitis. In this study, we investigated the safety of ASAI in patients 
with atopic dermatitis and bronchial asthma sensitized to house dust mites. In summary, ASAI was safe and well tolerated in 
patients with atopic dermatitis, suggesting that ASAI can be a useful therapeutic option for atopic dermatitis. 